Stephen Ronan Foley
Overview
Explore the profile of Stephen Ronan Foley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landsburg D, Frigault M, Heim M, Foley S, Hill B, Schofield G, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39924174
Background: Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2...
2.
Schuster S, Tam C, Borchmann P, Worel N, McGuirk J, Holte H, et al.
Lancet Oncol
. 2021 Sep;
22(10):1403-1415.
PMID: 34516954
Background: In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response rate was 52% and the...
3.
Thudium Mueller K, Grupp S, Maude S, Levine J, Pulsipher M, Boyer M, et al.
Blood Adv
. 2021 Aug;
5(23):4980-4991.
PMID: 34432863
Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric...
4.
Awasthi R, Pacaud L, Waldron E, Tam C, Jager U, Borchmann P, et al.
Blood Adv
. 2020 Feb;
4(3):560-572.
PMID: 32045475
The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated...
5.
Denisova G, Denisov D, Evelegh C, Weissgram M, Beck J, Foley S, et al.
PLoS One
. 2009 Apr;
4(4):e5309.
PMID: 19390580
Background: Antigen-based (as opposed to whole organism) vaccines are actively being pursued for numerous indications. Even though different formulations may produce similar levels of total antigen-specific antibody, the composition of...